1. Introduction {#sec1}
===============

Focal drug delivery in inner ear therapy, especially through transtympanic injection, has recently gained increasing popularity, partially because of its convenience, efficiency, and reduced systemic drug exposure and associated adverse effects ([@bib24], [@bib39]). Alternatively, [@bib28] reported that postaurical single injection of betamethasone was more effective in treating intractable low-frequency sensorineural hearing loss than oral administration of Merislon and Sibelium for two weeks ([@bib28]). Subsequently, postaurical injection of therapeutics was also employed to treat sudden deafness and tinnitus ([@bib6], [@bib17], [@bib27]). Potential existence of a direct transportation channel from the postaurical area to the inner ear was reported to support the postaurical injection approach ([@bib18]). Postaurical injection reportedly induced greater distribution of gadolinium chelate in the inner ear of guinea pigs than did intravenous injection ([@bib15]). The authors believed that postaurical injection was a noninvasive method of focal drug delivery ([@bib15]).

I doubt on the reports associated with postaurical injection. Based on anatomy, there is no direct transportion channel from the postaurical area to the inner ear. Theoretically, postaurical injection is a type of hypodermic injection that would never induce different distribution of agents in the inner ear between the ipsilateral and the contralateral sides. Defining postaurical injection as a noninvasive method is conceptually incorrect because the needle has to penetrate the skin, which is an invasive procedure ([@bib15]). In order to support my opinion, the present study tracked the dynamic distribution of gadolinium-tetra-azacyclo-dodecane-tetra-acetic acid (Gd-DOTA) in the surrounding tissues and inner ear of rat after postaurical injection by following a previously reported protocol (the reported concentration should be 0.5 mol/L instead of 0.5 mmol/L) ([@bib15]).

2. Materials and methods {#sec2}
========================

Nine male Sprague Dawley rats, weighing between 266 g and 635 g, were provided by and maintained in the Biomedicum Helsinki Laboratory Animal Centre of the University of Helsinki. Four rats were assigned in the experimental group of postaurical injection of Gd-DOTA and five rats were employed as controls receiving targeted tympanic medial wall delivery ([@bib35]). All the animal experiments were approved by the Ethical Committee of the University of Tampere (permit number: LSLH-2006-4143/Ym23). Animal care and the experimental procedures were conducted in accordance with the pertinent European legislation. During the experiments, animals were anesthetized with isoflurane (Piramal Healthcare, Boise, USA) using a 5% isoflurane--oxygen mixture (flow-rate 1.0 L/min) for induction and 3% isoflurane--oxygen mixture for maintenance via a facemask with the animals\' eyes protected with Viscotears^®^ (Novartis Healthcare A/S, Denmark).

A 4.7 T MR scanner with a bore diameter of 155 mm (PharmaScan, Bruker BioSpin, Ettlingen, Germany) in combination with a dedicated rodent head coil (linear birdcage coil, diameter 38 mm) was used for *in vivo* MR measurements. The body temperature of the rat was maintained by circulating warm water and respiration was recorded using the Physio Tool-1.0.b.2 program (Bruker, Ettlingen, Germany). After postaurical injection of Gd-DOTA on the left side at a dosage of 1.5 mmol/kg, the rat was placed in the MR scanner with ears positioned at the isocentre for imaging. In the control group, 2.5 μl Gd-DOTA (0.5 mol/L) (0.0031 mmol/kg in average) was injected onto the tympanic medial wall of the left ear using the custom-made device that was previously reported and the rats were kept in a lateral position with the injected ear up for 15 min before imaging ([@bib35]). After establishing inner ear geometry using a T2-weighted rapid acquisition with relaxation enhancement (RARE) sequence, the Gd-DOTA uptake in the inner ear was evaluated using a T1-weighted RARE sequence and a fluid-attenuated inversion-recovery (FLAIR) sequence for 2-dimensional (2D) and 3D images as reported earlier ([@bib35], [@bib36]). The parameters for these sequences are as follows. RARE sequence for T2-weighted 2D images: TR/TE~eff~ 2500/40 ms, RARE factor 8, matrix size 256 × 256, slice thickness 0.8 mm, FOV 5.0 × 5.0 cm^2^, resolution 0.195 × 0.195 mm^2^, NEX 3. RARE sequence for T1-weighted images: TR/TE~eff~ 500/10 ms, RARE factor 4, matrix size 256 × 192, slice thickness 0.5 mm, FOV 2.5 × 2.5 cm^2^, resolution 0.098 × 0.13 mm^2^, NEX 33. RARE sequence for T1-weighted 3D images: TR/TE~eff~ 500/12 ms, RARE factor 16, matrix size 64 × 64 × 64, FOV 0.89 × 0.89 × 0.89 cm^3^, resolution 0.139 × 0.139 × 0.139 mm^3^, NEX 2. FLAIR sequence for 2D images: TR/TE~eff~ 8000/40 ms, inversion time 1800 ms, RARE factor 16, matrix size 256 × 192, slice thickness 0.5 mm, FOV 3.0 × 3.0 cm^2^, resolution 0.117 × 0.156 mm^2^, NEX 7. In the group of postaurical injection, distribution of Gd-DOTA from the injection site towards the surrounding area was followed from 5 min through 42 min after injection. Distribution of Gd-DOTA in the inner ear was followed from 45 min through 101 min after injection. MRI was repeated in one rat one week after the injection. Animals in the control group were imaged at the time points of 30 min, 43 min, 60 min, 70 min, 4 h, 6 h, and 2 d after administration.

The ParaVision PV 4.0 (Bruker, Ettlingen, Germany) software was used for post-processing and quantification of MR images. The IBM SPSS statistics 23 software was employed for statistical analysis. Signal intensities in the region of interests (the scala tympani, scala vestibuli and vestibulum), and the average values between the ipsilateral and contralateral ears during the period of 45--101 min were compared using paired-samples *t*-test. Signal intensities in the ipsilateral inner ear of the targeted tympanic medial wall delivery group at the time points of 30 min and 60 min were compared to that of the postaurical injection group at time points of 45 min and 73 min using independent-samples *t*-test (this arrangement would not underestimate the inner ear signal in the postaurical injection group because the uptake did not reach a plateau during the observation time of 101 min). p-values below 0.05 were considered statistically significant.

3. Results {#sec3}
==========

Dynamic distribution of Gd-DOTA in the injection area and surrounding tissues is demonstrated in [Fig. 1](#fig1){ref-type="fig"}. Owing to T~2~\*-related signal loss ([@bib10]), the MRI signal in the center of injection site (fluid), which mainly located hypodermically, was fully eliminated during the observation period of 42 min, but Gd-DOTA was always detected in the skin ([Fig. 1](#fig1){ref-type="fig"}A--D). At 5 min after postaurical injection, Gd-DOTA distributed mainly in the tissues surrounding the bulla, temporal bone and skull on the ipsilateral side ([Fig. 1](#fig1){ref-type="fig"}A). At 42 min, Gd-DOTA arrived at the nearby neck space and the temporal bone and skull on the contralateral side ([Fig. 1](#fig1){ref-type="fig"}B and C). The signal in the inner ear was weak ([Fig. 1](#fig1){ref-type="fig"}D). In the control group of targeted tympanic medial wall delivery, Gd-DOTA was absent in the tissues surrounding the bulla. However, dynamic accumulation of Gd-DOTA in the laryngopharynx was observed during the period of 90 min through 6 h after administration ([Fig. 1](#fig1){ref-type="fig"}E and F).Fig. 1Different distribution of Gd-DOTA in the surrounding area after postaurical injection and targeted tympanic medial wall delivery in rats shown by MRI. Gd-DOTA was injected on the left side (L), and the right side (R) without injection was assigned as control. Two-dimensional T1-weighted RARE sequence was used to acquire the images at various time points. Bu: bulla; coch: cochlea; Gd-DOTA: Gd-DOTA liquid; Gd-DOTA-IE: Gd-DOTA in the inner ear; Gd-DOTA-LP: Gd-DOTA in the laryngopharynx; LP: laryngophayynx; Mas: masseter; Mas-c: masseter of the contralateral side; NS: neck space; Sk: skull; Tem: temporal bone; Tem-c: temporal bone of the contralateral side; Vest: vestibule. The scale bars on the left were created by the ParaVision PV 4.0 software.

In the inner ear, Gd-DOTA was equally taken up on both the ipsilateral and contralateral sides on images acquired using either the T2-weighted RARE or FLAIR sequence ([Fig. 2](#fig2){ref-type="fig"}). The MRI acquired using the FLAIR sequence demonstrated higher contrast effect than that using the T1-weighted RARE sequence. However, the latter demonstrated better anatomy than did the former. There was an insignificant difference in the signal intensity between the ipsilateral and contralateral sides and the uptake of Gd-DOTA in the inner ear did not reach a plateau during the observation time of 101 min ([Fig. 3](#fig3){ref-type="fig"}). After one week, Gd-DOTA signal disappeared in the inner ear. In the control group of targeted tympanic medial wall delivery, intense signal was detected in the vestibule and lower turns of the cochlea even at the early time point of 30 min after administration ([Fig. 4](#fig4){ref-type="fig"}A--C). Gd-DOTA reached at apex of the cochlea at 60 min and evenly distributed in the cochlea at 70 min post-administration ([Fig. 4](#fig4){ref-type="fig"}F and G). Extremely strong signal was demonstrated in the cochlea at 4 h after delivery ([Fig. 4](#fig4){ref-type="fig"}H and I). Gd-DOTA appeared in the Eustachian tube on the ipsilateral side at 30 min and augmented at 60 min after delivery, indicating the secretion pathway of the excessive Gd-DOTA from the middle ear towards the laryngopharynx ([Fig. 4](#fig4){ref-type="fig"}A and E). The signal intensities in the ipsilateral inner ear of the targeted tympanic medial wall delivery group at the time points of 30 min and 60 min were significantly higher than those in the postaurical injection group at corresponding time points ([Fig. 5](#fig5){ref-type="fig"}). Regarding the average value in the vestibulum and scala vestibuli and tympani, signal intensity in the targeted tympanic medial wall delivery group at the time points of 30 min and 60 min was respectively 4.6-fold and 3.7-fold greater than those in the postaurical injection group. Notably, the total dose of Gd-DOTA delivered to individuals using the targeted tympanic medial wall approach was only 0.1% of that using postaurical injection. Gd-DOTA was almost undetectable from the ipsilateral inner ear 2 d after administration. There was no distribution of Gd-DOTA in the inner ear of the contralateral side during the experimental period of 2 d.Fig. 2Dynamic uptake of Gd-DOTA in rat inner ear after postaurical injection detected by MRI. Gd-DOTA was injected on the left side (L), and the right side (R) without injection was assigned as control. Either 2-dimensional T1-weighted RARE or fluid-attenuated inversion-recovery (FLAIR) sequence was utilized to acquire the MRI. Am: ampulla; BS: brain stem; Coch: cochlea; L: left side; R: right side; SM: scala media; ST: scala tympani; SV: scala vestibuli, Vest: vestibulum; 1H: first higher turn; 1L: first lower turn; 2H: second higher turn; 2L: second lower turn. Scale bar = 5 mm.Fig. 3Quantificational changes in the MRI signal intensities of the rat inner ear after postaurical injection of Gd-DOTA. The images were acquired using either T1-weighted RARE (A) or FLAIR (B) sequence. There was insignificant difference between the injection side (left, L) and control side (right, R) ears at the defined time points (p \> 0.05, paired-samples t-test). n = 4. Ave: average value of the signal intensities in the scala tympani (ST), scala vestibuli (SV) and vestibulum (Vest); AU: arbitrary unit.Fig. 4Dynamic uptake of Gd-DOTA in rat inner ear after targeted tympanic medial wall delivery shown by MRI. Images were acquired using 2-dimensional (2D) and 3D T1-weighted RARE sequences. Am: ampulla; BS: brain stem; Coch: cochlea; ET: Eustachian tube; L: left side; R: right side; SCC: semicircular canal; ST: scala tympani; SV: scala vestibuli; Vest: vestibulum; 1H: first higher turn; 1L: first lower turn; 2H: second higher turn; 2L: second lower turn. The scale bars on the left were created by the ParaVision PV 4.0 software.Fig. 5Comparing the signal intensities in various inner ear area of the ipsilateral side after postaurical injection and targeted tympanic medial wall delivery of Gd-DOTA in rats. MRIs were obtained using T1-weighted RARE sequence. 30 min: 30 min after targeted tympanic medial wall delivery (TMW) and 45 min after postaurical injection (PA). 60 min: 60 min after TMW and 73 min after PA. \*P \< 0.05, \*\*p \< 0.01 (independent-samples t-test). n = 4 (in PA) or 5 (in TMW). Ave: average value of the signal intensities in the scala tympani (ST), scala vestibuli (SV) and vestibulum (Vest); AU: arbitrary unit.

4. Discussion {#sec4}
=============

Distribution of Gd-DOTA in the tissues surrounding the bulla at the earliest time after postaurical injection confirmed that the injection was accurate. The results that postaurical injection induced symmetric distribution of Gd-DOTA on both the ipsilateral and contralateral sides in the inner ear suggest that postaurical injection is not a focal delivery method but a systemic administration similar to hypodermic injection ([@bib1867], [@bib20]). It is strange that Li et al. defended that postaurical hypodemic injection is not a systemic delivery ([@bib16]). That the injected Gd-DOTA did not directly enter the inner ear from the postaurical area proved that there is not any direct channel from the poataurical area to the inner ear. Instead, Gd-DOTA entered the circulation system after diffusing in the surrounding tissues and spaces where there are plenty of capillary beds (lymph capillaries) to enable absorption of the delivered agents ([@bib3], [@bib5], [@bib23]). Although there is no ethical problem to deliver therapeutics through postaurical injection from the scientific point of view, we should not expect any dramatic therapeutic effect super to other systemic administrations because the agents need to pass through the blood-perilymph barrier and reach the target cells in contact with the perilymph ([@bib26], [@bib30]). The blood-perilymph barrier provides limited passages for almost all agents in order to maintain the homeostasis of the inner ear ([@bib2], [@bib13], [@bib19], [@bib25]). Injecting high dose of therapeutics may induce sufficient loading of the agents in the inner ear, however this may cause associated adverse effects in other organs such as the kidney and liver.

Alternatively, focal intratympanic administration bypasses the blood-perilymph barrier and transports the agent into the inner ear through the round and oval windows ([@bib7], [@bib24], [@bib39], [@bib35], [@bib36], [@bib31], [@bib37]). Since agents are not diluted by the serum that occurs in systemic administration, a high concentration gradient of agents from the middle ear to the perilymph contributes to enrichment of agents in the inner ear transportated across the round and oval windows. Intratympanic corticosteroids injections are reportedly beneficial in treating idiopathic sudden sensorineural hearing loss, Meniere\'s disease and noise-induced hearing loss ([@bib8], [@bib9], [@bib12], [@bib14], [@bib22], [@bib29]). In order to further reduce accumulation of agents in unwanted areas in individuals, we reported a targeted tympanic medial wall delivery method ([@bib35]). Both Gd-DOTA and superparamagnetic iron nanoparticles have been administered in rats making use of this method ([@bib35], [@bib40]). We also observed efficient uptake of dimeglumine gadopentetate in the inner ear of patients with Meniere\'s disease after administration using this method ([@bib41]). The present study showed that there was insignificant distribution of Gd-DOTA in surrounding tissues and spaces while abundant uptake in the inner ear was achieved after targeted tympanic medial wall delivery. The average signal intensity in the inner ear of the targeted tympanic medial wall delivery group at the time points of 30 min and 60 min was respectively 4.6-fold and 3.7-fold greater than those in the postaurical injection group. However, the total amount of administered agents using the targeted tympanic medial wall approach was only 0.2% of that using postaurical injection. It suggests that the targeted focal delivery method is more effective than postaurical injection with the possibility of maximally avoiding adverse effects in the kidney and liver associated with drug delivery.

There are several additional scientific errors in the recently published article ([@bib16]). The statement that "there is no interaction between the *in vivo* contrast agent gadopentetate dimeglumine and the inner ear tissues" contradicts to the author\'s own results showing appearance of the contrast agent in the inner ear perilymph. The authors complained that intravenous injection did not induce endolymphatic distribution of agents. Actually, it is unnecessary for the therapeutics to enter the endolymph because the target cells are available to the perilymph. More importantly, drug delivery should not disrupt the endolymphatic space in order to maintain the inner ear function ([@bib11], [@bib21], [@bib26], [@bib38]). The old term of "blood-labyrinth barrier" in the article should be updated to "blood-perilymph barrier and blood-endolymph barrier" because of their significantly different composition and biological functions ([@bib33], [@bib34]). The updated terms of inner ear biological barriers are helpful for the clinician to understand the pharmaceutical mechanism of the inner ear therapy.

It is obvious that the physicochemical characteristics of Gd-DOTA is not identical to that of steroids. However, the uptake behavior of Gd-DOTA in the inner ear resembled that of steroids following either intravenous or intratympanic injection ([@bib1], [@bib4], [@bib32], [@bib35], [@bib31], [@bib30], [@bib33]). This suggests that the results obtained using the MRI contrast agent of Gd-DOTA can be applied to predict the dynamics of steroids in the inner ear after similar administrations.

To conclude, postaurical injection induced symmetric distribution of Gd-DOTA on both the ipsilateral and contralateral sides in the inner ear in addition to the surrounding tissues and spaces, proving that postaurical injection is a systemic administration similar to hypodermic injection rather than a focal delivery method. By contrast, targeted tympanic medial wall delivery induced fast and abundant uptake of Gd-DOTA in the inner ear without significant distribution in unwanted areas.

The study was supported by the 1255 project of Changhai Hospital, Second Military Medical University, Shanghai, China.

Peer review under responsibility of PLA General Hospital Department of Otolaryngology Head and Neck Surgery.
